Vanessa Gascoigne

Vanessa Gascoigne is the director of Merck Sharpe & Dome (MSD) in New Zealand, where she plays a key role in advocating for the funding and accessibility of cancer treatments. Recently, she has been in the news discussing the need for expanded access to the immunotherapy drug Keytruda for patients with high-risk early-stage triple negative breast cancer, emphasizing the importance of removing financial barriers to essential medicines for those affected by this aggressive disease.